Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DATA-MIDCAB antiplatelet strategies after minimally invasive CABG
ChiCTR2000028841Phase 4Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Aug 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ticagrelor and aspirin in coronary arteriosclerosis (3 arms), sponsored by Peking University Third Hospital. Primary endpoint: Ratio of vessels open without bleeding. Planned start Aug 2019; status: not yet recruiting.
02
Drugs
ticagreloraspirin
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2000028841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000028841.